EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IMPDH inhibition enhances cytarabine efficacy in SAMHD1 ‐expressing leukaemia cells via guanine nucleotide depletion

Miriam Yagüe-Capilla iD, Christopher Dirks, Caroline Eiden, Sonja K Fesenmayer, Femke M Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G Rudd iD

Molecular Oncology · 2026-11 · 20 (11) · 2936-2954

DOI: 10.1002/1878-0261.70226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 19.02.2026. Verfasst von Miriam Yagüe-Capilla und 9 weiteren Autor:innen. Beteiligte Einrichtung: Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: SAM Domain and HD Domain-Containing Protein 1, Cytarabine, IMP Dehydrogenase, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Åke Wiberg Stiftelse, Stiftelsen Clas Groschinskys Minnesfond, Dr Åke Olssons Stiftelse för Haematologisk Forskning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nucleoside analogue cytarabine (ara‐C) is part of standard treatment against acute myeloid leukaemia (AML). The efficacy of this therapy is dependent upon accumulation of the active triphosphate metabolite ara‐CTP, which mis‐incorporates into genomic DNA, triggering cell death. The deoxyribonucleoside triphosphate triphosphohydrolase (dNTPase) SAMHD1 can hydrolyse ara‐CTP and thereby convert the active metabolite back to its inactive prodrug form. This constitutes a barrier to treatment efficacy and thus strategies to target SAMHD1 are warranted. SAMHD1 activity is allosterically regulated by nucleotides, which are synthesised in cells via distinct pathways. We screened a collection of drugs targeting nucleotide biosynthetic enzymes and identified that inhibition of inosine‐5′‐monophosphate dehydrogenase (IMPDH), responsible for catalysing the rate‐limiting step in guanine nucleotide biosynthesis, sensitises AML cell lines to ara‐C in a SAMHD1‐dependent manner. We show that approved drugs inhibiting IMPDH—mycophenolic acid and ribavirin—imbalance deoxyribonucleoside triphosphate pools and increase ara‐C efficacy in SAMHD1‐proficient, but not deficient, leukaemic cells. Altogether, we provide insight into SAMHD1 regulation in leukaemic cells and show how this process can be exploited by approved drugs to improve ara‐C therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SAM Domain and HD Domain-Containing Protein 1CytarabineIMP DehydrogenaseLeukemia, Myeloid, AcuteGuanine NucleotidesEnzyme InhibitorsHumansCell Line, TumorMycophenolic AcidRibavirin

Stichwörter der Autor:innen

acute myeloid leukaemiachemoresistancedNTP metabolismdrug repurposing

Substanzen

SAM Domain and HD Domain-Containing Protein 1CytarabineSAMHD1 protein, humanIMP DehydrogenaseGuanine NucleotidesMycophenolic AcidRibavirinEnzyme Inhibitors

Autor:innen und Institutionen

  • Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain.
  • Departamento de Biología Celular, Facultad de Biología, Universidad de Sevilla, Spain.
  • Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Section of Paediatric Oncology, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Miriam Yagüe-Capilla, Sean G Rudd

Förderung

  • Åke Wiberg Stiftelse
  • Stiftelsen Clas Groschinskys Minnesfond
  • Dr Åke Olssons Stiftelse för Haematologisk Forskning
  • Svenska Sällskapet för Medicinsk Forskning
  • Karolinska Institutet
  • Stiftelsen Felix Mindus Bidrag till Leukemiforskningen
  • Vetenskapsrådet
  • Barncancerfonden

Zitieren

APA

Yagüe-Capilla, M., Dirks, C., Eiden, C., Fesenmayer, S. K., Hormann, F. M., Klootsema, Y., Lilienthal, I., Zhang, S. M., Herold, N., & Rudd, S. G. (2026). IMPDH inhibition enhances cytarabine efficacy in SAMHD1 ‐expressing leukaemia cells via guanine nucleotide depletion. Molecular Oncology, 20(11), 2936-2954. https://doi.org/10.1002/1878-0261.70226

Vancouver

Yagüe-Capilla M, Dirks C, Eiden C, Fesenmayer SK, Hormann FM, Klootsema Y, et al. IMPDH inhibition enhances cytarabine efficacy in SAMHD1 ‐expressing leukaemia cells via guanine nucleotide depletion. Molecular Oncology. 2026;20(11):2936-2954. doi:10.1002/1878-0261.70226

BibTeX
@article{YageCapilla2026,
  author = {Yagüe-Capilla, Miriam and Dirks, Christopher and Eiden, Caroline and Fesenmayer, Sonja K and Hormann, Femke M and Klootsema, Yolande and Lilienthal, Ingrid and Zhang, Si Min and Herold, Nikolas and Rudd, Sean G},
  title = {IMPDH inhibition enhances cytarabine efficacy in SAMHD1 ‐expressing leukaemia cells via guanine nucleotide depletion},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {11},
  pages = {2936--2954},
  doi = {10.1002/1878-0261.70226}
}
Kostenlos starten →